To evaluate the impact of the 23-valent pneumonia vaccine on the incidence of pulmonary infection and survival in lung cancer patients, and to explore its preventive effect and safety in the lung cancer patients.
Male or female patients >=18 years of age;
Histological diagnosis of NSCLC, including both non-small cell lung cancer and small cell lung cancer, regardless of whether they are in the early, locally advanced stage or advanced stage, and regardless of whether they have received surgery, radiotherapy, chemotherapy or other treatments;
Never received pneumococcal vaccine
None
Lung cancer patients can receive or not receive the 23-valent pneumococcal vaccine
Cohort
Prospective
23-valent pneumococcal vaccine
Biological/VaccineReceive the 23-valent pneumococcal vaccine; Do not receive the 23-valent pneumococcal vaccine
The incidence of pneumonia at 12 months
During the 12-month follow-up period, the incidence of pulmonary infection in lung cancer patients was evaluated through regular clinical examinations, imaging tests, and laboratory tests.
Incidence of pneumonia
The proportion of lung cancer patients who developed pneumonia during the study period.
Survival rate
The survival rate of lung cancer patients within a specific time period (such as 1 year, 2 years, or 5 years).
Lung cancer-related complications
The incidence of complications related to lung cancer (such as respiratory failure, infection, etc.).
Length of hospital stay
Record the number of days of hospitalization for patients hospitalized due to lung infection.
Hospitalization rate
The proportion of patients hospitalized due to pneumonia or other related complications.
Antibiotic usage
This includes the types, dosages, and durations of antibiotic usage, etc
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
